Clinical Trials Directory

Trials / Conditions / Bevacizumab

Bevacizumab

25 registered clinical trials studyying Bevacizumab — 12 currently recruiting.

StatusTrialSponsorPhase
RecruitingBevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
NCT07481786
Sun Yat-sen UniversityPhase 3
RecruitingQL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
NCT07327788
Nanfang Hospital, Southern Medical UniversityPhase 2
Enrolling By InvitationEfficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in
NCT07445347
Poitiers University Hospital—
SuspendedPhase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab
NCT07011550
M.D. Anderson Cancer CenterPhase 2
RecruitingLow-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
NCT07085169
Ruijin HospitalPhase 2
Not Yet RecruitingEfficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progressio
NCT07004335
Hebei Medical University Fourth HospitalPhase 4
RecruitingNeoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-adv
NCT06755684
Peng ZhangPhase 2
RecruitingdTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
NCT06609863
Sun Yat-sen UniversityN/A
Not Yet RecruitingEfficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
NCT06539559
Wang JiayuPhase 2
RecruitingCryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastase
NCT06265350
Sun Yat-sen UniversityN/A
RecruitingSingle Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable
NCT05970666
The First Affiliated Hospital of Xiamen UniversityPhase 2
RecruitingXELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
NCT05970302
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2
CompletedStudy to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients W
NCT05807893
Sun Yat-sen UniversityPhase 2 / Phase 3
UnknownNeoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
NCT05111860
Shanghai Minimally Invasive Surgery CenterPhase 1 / Phase 2
UnknownAlbumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
NCT05310344
Lei LiPhase 2
CompletedBevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
NCT05263947
Tianjin Medical University Cancer Institute and HospitalPhase 2
UnknownThe Effects of Preoperative Bevacizumab on Perioperative Complications
NCT04788381
Second Affiliated Hospital, School of Medicine, Zhejiang University—
UnknownHAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama
NCT04627363
Sun Yat-sen UniversityPhase 2
RecruitingLocoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
NCT06323382
Sun Yat-sen University—
UnknownEfficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian
NCT04556071
Xiaoxiang ChenPhase 2
UnknownSintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
NCT04213170
Sun Yat-sen UniversityPhase 2
CompletedPemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-S
NCT01951482
Sun Yat-sen UniversityPhase 3
CompletedStudy of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblasto
NCT01810744
Centre Georges Francois LeclercN/A
UnknownObservational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherap
NCT01652560
LiNanlin,Ph.D, Chief Physician,Clinical Professor—
CompletedTopical Bevacizumab for Preventing Recurrent Pterygium
NCT01311960
Chulalongkorn UniversityPhase 3